Table 1 Demographic and clinical characteristics of participants in the ADAPT Study
Total | Matched Control | Long-COVID | |
|---|---|---|---|
N = 62 [n (%)] | N = 31 [n (%)] | N = 31 [n (%)] | |
Age (median, IQR) | 50.5 (40–60) | 50 (39–60) | 51 (40–60) |
Gender | |||
Female | 32 (52%) | 16 (52%) | 16 (52%) |
Male | 30 (48%) | 15 (48%) | 15 (48%) |
Race/ethnicity | |||
Caucasian/White | 54 (87%) | 26 (84%) | 28 (90%) |
Other than Caucasian/White | 8 (13%) | 5 (16%) | 3 (10%) |
Enrolment source | |||
Community | 52 (84%) | 29 (94%) | 23 (74%) |
Inpatient | 10 (16%) | 2 (6%) | 8 (26%) |
Complete 24-month visit | |||
No | 15 (24%) | 8 (26%) | 7 (23%) |
Yes | 47 (76%) | 23 (74%) | 24 (77%) |
Vaccine type | |||
No vaccination | 9 (15%) | 5 (16%) | 4 (13%) |
AstraZeneca | 27 (44%) | 13 (42%) | 14 (45%) |
Pfizer | 26 (42%) | 13 (42%) | 13 (42%) |
Days to first vaccination (median, IQR)a | 474 (429, 507) | 480 (429, 517) | 467 (426, 490) |
New COVID infection during follow-up | |||
No | 46 (74%) | 23 (74%) | 23 (74%) |
Yes | 16 (26%) | 8 (26%) | 8 (26%) |
Routine pathology at 4-months post infection | |||
C reactive protein | 0.8 (0.4–1.6) | 0.8 (0.4–2.0) | 0.9 (0.5–1.5) |
D-Dimer | 0.3 (0.3–0.4) | 0.3 (0.3–0.3) | 0.3 (0.3–0.4) |
Lymphocyte count | 1.6 (1.4–2.0) | 1.5 (1.4–1.8) | 1.8 (1.4–2.2) |
Total cholesterol | 5.0 (4.3–5.7) | 4.8 (4.3–6.2) | 5.0 (4.3–5.6) |
Troponin I | 2.0 (2.0–4.0) | 2.0 (2.0–4.0) | 3.0 (2.0–4.0) |
BSL /Glucose | 5.0 (4.6–5.4) | 4.8 (4.7–5.4) | 5.0 (4.6–5.3) |
Neutrophil count | 3.0 (2.4–3.6) | 3.0 (2.4–4.0) | 2.9 (2.4–3.5) |
Platelet | 223 (196–251) | 211 (194–252) | 227 (201–251) |
